Dr. Joshua Okay. Sabari sat down with Dr. Daniel V. Araujo to debate topline takeaways from the 2025 ASCO Annual Assembly throughout the realm of genitourinary oncology, spanning prostate and bladder cancers. Within the interview, the pair coated updates from the AMPLITUDE trial evaluating sufferers with prostate most cancers, in addition to mentioned the utility of circulating tumor DNA (ctDNA) in muscle-invasive bladder most cancers
Sabari is the editor in chief of CURE, in addition to the assistant professor within the Division of Medication at NYU Grossman College of Medication and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Heart. Araujo serves as a medical oncologist on the College of Florida Well being (UF) Well being.
The pair started by delving into the AMPLITUDE trial, a randomized managed trial, investigating the position of Akeega (niraparib plus abiraterone acetate [Zytiga]) versus Zytiga for sufferers with metastatic hormone-sensitive prostate most cancers whose illness has homologous recombination restore (HRR) gene defects.
Throughout a presentation shared on the ASCO Assembly, investigators revealed that with the investigative mixture, there was a 37% discount within the threat of radiographic development or demise in contrast with the placebo mixture on this beforehand handled affected person inhabitants. Furthermore, the danger symptomatic development was considerably decreased by 50% with the investigative mixture versus placebo. Total survival information, although not statically important but, are additionally exhibiting tendencies in direction of enchancment with Akeega.
“This information will probably be assessed by the FDA and different regulators,” Araujo stated of the information mentioned.
Additionally throughout their dialog, Sabari and Araujo broke down the present position of ctDNA within the genitourinary cancers panorama. ctDNA are small items of DNA which may be detected and are launched by tumor cells into an individual’s blood. If detected early, ctDNA has the potential to information remedy selections, and has already displayed a prognostic impact in these with muscle-invasive bladder most cancers.
“Right here, we’re seeing in bladder most cancers the utilization of ctDNA, as you talked about, and as a molecular biomarker to assist probably information remedy. [These are] very thrilling updates,” Sabari concluded.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
